Lyrica
Jul 25, 2017
Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project
Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
